Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Efavirenz
Drug ID BADD_D00749
Description Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Indications and Usage For use in combination treatment of HIV infection (AIDS)
Marketing Status Prescription; Discontinued
ATC Code J05AG03
DrugBank ID DB00625
KEGG ID D00896
MeSH ID C098320
PubChem ID 64139
TTD Drug ID D07HVY
NDC Product Code 0056-0470; 65862-049; 0378-2233; 72865-172; 69988-0008; 65862-106; 65862-324; 64220-195; 70518-3258; 64980-406; 53104-7544; 69097-301; 64380-889; 70966-0025; 65015-641; 70366-002; 31722-504; 70518-1100; 65862-105; 65015-868; 70518-2962; 67835-0001; 51407-382; 65862-267; 0056-0510; 48087-0062; 48087-0128; 42543-889; 65675-1584; 68554-0018; 48087-0131; 65862-104; 65015-836; 12783-0510; 64980-407; 0056-0474; 48087-0127; 68554-0042; 65015-859
Synonyms efavirenz | (s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | efavirenz, (S)-isomer | efavirenz, (R)-isomer | Stocrin | Sustiva | DMP 266 | DMP-266 | L 743726 | L-743726 | L 743,726 | L-743,726
Chemical Information
Molecular Formula C14H9ClF3NO2
CAS Registry Number 154598-52-4
SMILES C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatocellular injury09.01.07.0080.016821%Not Available
Hepatomegaly09.01.05.001--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
High density lipoprotein increased13.12.01.004--Not Available
HIV infection11.05.17.002; 10.03.03.0020.016821%Not Available
Hydrops foetalis18.03.02.0080.025232%Not Available
Hypercholesterolaemia14.08.01.0010.016821%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperlactacidaemia14.01.01.006--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.067286%
Hypertriglyceridaemia14.08.02.0010.033643%
Hypoaesthesia17.02.06.023--Not Available
Hypokalaemia14.05.03.002--
Hypokinesia17.01.02.0090.016821%Not Available
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.0020.075696%
Immune system disorder10.02.01.001--Not Available
Influenza like illness08.01.03.010--
Insomnia17.15.03.002; 19.02.01.0020.092518%
Insulin resistance14.06.02.003; 05.06.02.003--Not Available
Intestinal obstruction07.13.01.0020.016821%Not Available
Iritis10.02.01.022; 06.04.03.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.033643%Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.025232%Not Available
Kidney malformation20.01.06.004; 03.06.01.0060.016821%Not Available
Lactic acidosis14.01.01.002--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.042054%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages